I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Washington, D.C. 20231 on this 31st day of October 2001.

(Signature of person mailing) A. David Joran

(Typed or printed name of/person)

IN THE UNITED STATES PATENT

IN RE APPLICATION OF: De Raspide, Manaud P.F.

APPLICATION NO.: 09/912,774 Examiner: Not Yet Known

FILING DATE: July 25, 2001 Group Art Unit: 1614

PARTICULATE COMPOSITION OF TITLE:

ELETRIPTAN

Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted

Date: October 31, 2001

A. David Joran

Attorney for Applicant(s)

Reg. No. 37,858

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212) 733-3381